| ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia S Peirs, F Matthijssens, S Goossens, I Van de Walle, K Ruggero, ... Blood, The Journal of the American Society of Hematology 124 (25), 3738-3747, 2014 | 238 | 2014 |
| Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia C Vicente, C Schwab, M Broux, E Geerdens, S Degryse, S Demeyer, ... Haematologica 100 (10), 1301, 2015 | 170 | 2015 |
| JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model S Degryse, CE De Bock, L Cox, S Demeyer, O Gielen, N Mentens, ... Blood, The Journal of the American Society of Hematology 124 (20), 3092-3100, 2014 | 152 | 2014 |
| HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development CE de Bock, S Demeyer, S Degryse, D Verbeke, B Sweron, O Gielen, ... Cancer discovery 8 (5), 616-631, 2018 | 101 | 2018 |
| Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia S Degryse, CE De Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, ... Leukemia 32 (3), 788-800, 2018 | 84 | 2018 |
| Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes A Zaitsev, M Chelushkin, D Dyikanov, I Cheremushkin, B Shpak, K Nomie, ... Cancer Cell 40 (8), 879-894. e16, 2022 | 54 | 2022 |
| Distinct acute lymphoblastic leukemia (ALL)-associated Janus kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities E Losdyck, T Hornakova, L Springuel, S Degryse, O Gielen, J Cools, ... Journal of Biological Chemistry 290 (48), 29022-29034, 2015 | 49 | 2015 |
| Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors A Dagklis, S Demeyer, J De Bie, E Radaelli, D Pauwels, S Degryse, ... Blood, The Journal of the American Society of Hematology 128 (23), 2642-2654, 2016 | 48 | 2016 |
| JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia S Degryse, J Cools Journal of hematology & oncology 8, 1-5, 2015 | 39 | 2015 |
| Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL S Degryse, S Bornschein, CE de Bock, E Leroy, M Vanden Bempt, ... Blood, The Journal of the American Society of Hematology 131 (4), 421-425, 2018 | 35 | 2018 |
| Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma AJ Luginbuhl, JM Johnson, LA Harshyne, AJ Linnenbach, SK Shukla, ... Clinical Cancer Research 28 (5), 915-927, 2022 | 27 | 2022 |
| HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development. Cancer Discov. 2018; 8: 616–631. doi: 10.1158/2159-8290 CE De Bock, S Demeyer, S Degryse, D Verbeke, B Sweron, O Gielen, ... CD-17-0583.[Abstract][CrossRef][Google Scholar], 0 | 15 | |
| B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma I Dagogo-Jack, I Valiev, N Kotlov, A Belozerova, A Lopareva, A Butusova, ... JTO Clinical and Research Reports 4 (7), 100527, 2023 | 1 | 2023 |
| Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma CL Batlevi, G Nos, N Kotlov, M Sorokina, M Okwali, A Bagaev, L Michaud, ... Blood 140 (Supplement 1), 9228-9230, 2022 | 1 | 2022 |
| B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma I Valiev, N Kotlov, A Belozerova, A Lopareva, A Butusova, N Samarina, ... Cancer Research 82 (12_Supplement), 5172-5172, 2022 | 1 | 2022 |
| Predictors of treatment response in a preoperative window of opportunity trial of nivolumab in resectable squamous cell carcinoma of the head and neck N Kotlov, Z Antysheva, D Antonova, N Samarina, S Degryse, ... Cancer Research 81 (13_Supplement), 1441-1441, 2021 | 1 | 2021 |
| Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model CE de Bock, S Degryse, S Demeyer, B Sweron, O Gielen, N Mentens, ... Blood 124 (21), 1078, 2014 | 1 | 2014 |
| Gastric Cancer Tumor Immune Microenvironment Landscape: Clinical Implications for Patient Outcome and Response to PD-1 Immune Checkpoint Blockade M Shah, S Sarkar, D Melikhova, P Thakkar, O Kudryashova, N Shin, ... | | 2024 |
| ML quantification of tumor-Infiltrating lymphocytes distinguishes immune-phenotypes and reveals phenotypic heterogeneity N Le, B Rahsepar, J Hipp, J Conway, Y Gerardin, E Krause, C Shen, ... Cancer Research 84 (6_Supplement), 905-905, 2024 | | 2024 |
| Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making. I Zhuk, A Novokreschchenova, A Aukhadieva, S Degryse, A Shevkoplias, ... Journal of Clinical Oncology 41 (16_suppl), 11547-11547, 2023 | | 2023 |
